Holen Sie sich die Stockscreener-App
29.11
0.33%
-0.095
Handel nachbörslich:
28.28
-0.83
-2.85%
Schlusskurs vom Vortag:
$29.20
Offen:
$29.34
24-Stunden-Volumen:
199.56K
Relative Volume:
0.60
Marktkapitalisierung:
$2.01B
Einnahmen:
$751.00K
Nettoeinkommen (Verlust:
$-74.57M
KGV:
-26.39
EPS:
-1.1031
Netto-Cashflow:
$-55.52M
1W Leistung:
-0.44%
1M Leistung:
+14.92%
6M Leistung:
+98.43%
1J Leistung:
+90.26%
1-Tages-Spanne:
$28.87
$29.93
1-Wochen-Bereich:
$27.45
$29.93
52-Wochen-Spanne:
$12.56
$31.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
29.11 | 1.92B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
432.83 | 140.84B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
155.54 | 41.70B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.75 | 33.35B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
68.33 | 32.72B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
218.40 | 28.27B | 5.54B | 1.52B | 1.74B | 10.37 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | Mizuho | Outperform |
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to EBITDA forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to sales forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse Biosciences Inc (PLSE) Institutional Confidence - TradingKey
Pulse Biosciences stock hits 52-week high at $28.68 - Investing.com
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com - Investing.com UK
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (FWB:6L8) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8) - TradingView
6L8 Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth - Moomoo
Pulse Biosciences Inc (PLSE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting? - simplywall.st
Pulse Biosciences, Inc.(NasdaqCM:PLSE) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
Understanding Momentum Shifts in (PLSE) - Stock Traders Daily
Pulse Biosciences Stockweekly review and sector comparison - AD HOC NEWS
Pulse Biosciences Inc (PLSE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulse Biosciences Inc (PLSE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulse Biosciences Strengthens Executive Team - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulse Biosciences Inc (PLSE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLSE Q1 2026 Earnings: Narrower Loss Beats Expectations as Pulse Biosciences Advances CellFX PlatformRevenue Growth Outlook - dars.gov.et
What Could New Equity Awards Signal for Pulse Biosciences’ Ongoing Growth Efforts? - Kalkine Media
Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares - Stock Titan
What Do Pulse Biosciences’ New Equity Awards Reveal About Executive Compensation Trends? - Kalkine Media
Director at Pulse Biosciences (NASDAQ: PLSE) receives new stock option grants - Stock Titan
[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Pulse Biosciences Plunges Over 9% as Selling Pressure Intensifies, Key Support in PlayHigh Low Breadth - newsline.com
Pulse Bio to redeem remaining common stock warrants - MSN
Pulse Biosciences Shareholders Approve Board and Auditor Slate - TipRanks
Pulse Biosciences (PLSE) investors back all directors and Deloitte as 2026 auditor - Stock Titan
Pulse Biosciences (PLSE) Hovers Near Resistance After Modest GainVolume Breadth - newsline.com
Pulse Biosciences Stock (US73242P1030): Shares in focus after recent conference appearance - AD HOC NEWS
Pulse Biosciences (PLSE) upgraded to buy: What does it mean for the stock? - MSN
Pulse Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Pulse Biosciences (PLSE) Surges 7.6% on Increased Volume, Testing Key ResistanceSynthetic Short - newsline.com
PLSE: Directors and auditor ratified as company advances AFib trial and strengthens leadership - TradingView
Pulse Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) to Redeem Outstanding Warrants by June 2026 - GuruFocus
PLSE: Nanosecond PFA platform shows high efficacy in AFib, with FDA approval targeted for late 2027 - TradingView
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants - Investing News Network
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.31%
2.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):